RENX - RENALYTIX AI - Share Chat

Renalytix AI (LSE: RENX) is a UK-based precision medicine company focused on the early detection and management of kidney disease. Leveraging artificial intelligence, its flagship diagnostic platform, KidneyIntelX, combines patient data and biomarkers to provide an individualized risk assessment for progressive chronic kidney disease (CKD). This prognostic tool aims to stratify patients, enabling clinicians to make more informed treatment decisions and potentially prevent costly late-stage kidney failure. While initially targeting the substantial US Medicare market, the company has faced significant commercialisation and funding challenges, leading to recent strategic shifts and a focus on pathways to commercial viability. Its technology supports value-based care by facilitating proactive intervention in a growing global health crisis.